Phosphorothioated amino-AS1411 aptamer functionalized stealth nanoliposome accelerates bio-therapeutic threshold of apigenin in neoplastic rat liver: a mechanistic approach

Table 3 Quantitative data referring tumor development and total HAF (hepatic altered foci) area among different group of experimental animals

Treatment Groups	Number of the rat developed tumour post treatment	Average tumour volume (n = 6) (mm)³	Number of HAF area per cm² under microscopic observation on treatment
Gr A	0/6	–	–
Gr B	6/6	1502.89 ± 9.98^#	86.74 ± 5.90^#
Gr C	6/6	1261.5 8 ± 8.09^#$	67.89 ± 8.09^#^
Gr D	5/6	821.08 ± 4.67^#$	56.89 ± 6.06^#^^ns
Gr E	3/6	786.73 ± 5.56^#$ns	49.97 ± 0.58^#^**
Gr F	2/6	35.89 ± 7.56^#$***	12.63 ± 0.43^#^***
Gr G	0/6	–	–

^#Data represented mean ± SD (where, n = 6 in each group of animals)
^$^{,^} indicated significant (p < 0.05) reduction of tumor volume and HAF observed in (Gr C-Gr F) in comparison to positive control group Gr- B. Again, compared among the test nanoliposome (Gr D, Gr E, and Gr F), in Gr F (aptamer conjugated nanoliposome treated group) significant (p < 0.05) reduction of both tumor volume and HAF were observed mentioned in figure (***); while in Gr E (PEG-NLCs treated group showed non-significant (ns) amount of tumor volume reduction, (**) significant amount of HAF reduction and Gr D (NLCs treated animal group) showed non-significant (ns) amount of HAF reduction

ISSN: 1477-3155